Telangana has secured an investment of one billion US dollars from US pharma major Eli Lilly to expand its manufacturing and global medicine supply capacity in Hyderabad.
The announcement has been made after a delegation from the company met Telangana Chief Minister A Revanth Reddy and State Industries Minister D Sridhar Babu in Hyderabad yesterday. The company inaugurated its Global Capability Centre (GCC) in Hyderabad in August this year.
An official release stated that despite strong interest from several other states, Eli Lilly chose Telangana owing to the favourable ecosystem, availability of skilled manpower, infrastructure, and proactive government support.
It further said that with the new facilities, Eli Lilly is set to manufacture in Telangana and supply globally. The One-billion-dollar investment by Eli Lilly reflects the company’s interest in Telangana beyond its GCC operations and focuses on developing new medicines to treat diabetes and obesity, Alzheimer’s disease, cancer and autoimmune conditions.
US drugmaker Eli Lilly and Company will invest more than $1 billion in India over the next few years, as it looks to expand manufacturing and strengthen supply chains for some of its key medicines.
The company will work with local contract manufacturers and set up a new Manufacturing and Quality hub in Hyderabad to oversee production.
Hiring for the Hyderabad facility will begin immediately, with roles open for engineers, chemists, analytical scientists and quality specialists. Lilly said the hub will support its wider global manufacturing network and ensure a steady supply of medicines for conditions such as diabetes, obesity, Alzheimer’s, cancer and autoimmune diseases.
Patrik Jonsson, president of Lilly International, said the investment was part of the company’s effort to build global capacity. “We are making significant investments to increase manufacturing and medicine supply capacity around the world. India will play an important role in supporting our evolving portfolio,” he said.
The move comes after Lilly launched its weight-loss and diabetes drug Mounjaro in India earlier this year, a treatment that has seen strong global demand.
Analysts say the investment will help the company secure long-term supply at a time of intensifying competition in the obesity drug market.
Telangana Chief Minister A. Revanth Reddy welcomed the announcement, saying it highlighted Hyderabad’s growing importance in global healthcare.
Industries Minister Sridhar Babu also pointed to the state’s focus on technology-led growth and ease of doing business as a draw for multinational drugmakers.
Invest India CEO Nivruti Rai said Lilly’s plan highlighted India’s role as a competitive manufacturing hub for the pharmaceutical industry.
Since 2020, Lilly has committed more than $55 billion worldwide to expand production capacity, including in the United States, as it prepares for demand from new therapies.
The Indian investment adds another leg to that expansion and signals the company’s intent to make the country a key link in its global supply chain.